OBJECTIVES: Although many depressed patients with Alzheimer disease (AD) are treated with antidepressants, the effect of such treatment on cognitive performance in these patients is not known. The authors report cognitive outcomes in patients with depression of AD (dAD) after a 24-week trial of sertraline or placebo. DESIGN:Placebo-controlled, randomized, double-blind trial. SETTING:Outpatient memory clinics at five academic medical centers in the United States. PARTICIPANTS: A total of 131 patients with dAD (60 men) and Mini-Mental State Examination scores of 10-26. INTERVENTION: Sertraline (n = 67), target dose of 100 mg daily or matching placebo (n = 64). Caregivers received standardized psychosocial intervention throughout the trial. MEASUREMENTS: Mini-Mental State Examination, cognitive subscale of the Alzheimer's Disease Assessment Scale, letter fluency, backward digit span, Symbol Digit Modalities Test, and Finger Tapping Test, administered at baseline, and 8, 16, and 24 weeks following baseline. RESULTS: A series of linear models indicated no effect of treatment or of depression remission on cognitive test performance at 24 weeks. Regardless of treatment condition, very little change in cognitive test performance was noted in general. CONCLUSIONS: Treatment with sertraline in patients with dAD is not associated with greater improvement in cognition at week 24 than treatment with placebo.
RCT Entities:
OBJECTIVES: Although many depressedpatients with Alzheimer disease (AD) are treated with antidepressants, the effect of such treatment on cognitive performance in these patients is not known. The authors report cognitive outcomes in patients with depression of AD (dAD) after a 24-week trial of sertraline or placebo. DESIGN: Placebo-controlled, randomized, double-blind trial. SETTING:Outpatient memory clinics at five academic medical centers in the United States. PARTICIPANTS: A total of 131 patients with dAD (60 men) and Mini-Mental State Examination scores of 10-26. INTERVENTION: Sertraline (n = 67), target dose of 100 mg daily or matching placebo (n = 64). Caregivers received standardized psychosocial intervention throughout the trial. MEASUREMENTS: Mini-Mental State Examination, cognitive subscale of the Alzheimer's Disease Assessment Scale, letter fluency, backward digit span, Symbol Digit Modalities Test, and Finger Tapping Test, administered at baseline, and 8, 16, and 24 weeks following baseline. RESULTS: A series of linear models indicated no effect of treatment or of depression remission on cognitive test performance at 24 weeks. Regardless of treatment condition, very little change in cognitive test performance was noted in general. CONCLUSIONS: Treatment with sertraline in patients with dAD is not associated with greater improvement in cognition at week 24 than treatment with placebo.
Authors: Cynthia A Munro; Jason Brandt; Jeannie-Marie E Sheppard; Cynthia D Steele; Quincy M Samus; Martin Steinberg; Peter V Rabins; Constantine G Lyketsos Journal: Am J Geriatr Psychiatry Date: 2004 Sep-Oct Impact factor: 4.105
Authors: Daniel Weintraub; Paul B Rosenberg; Lea T Drye; Barbara K Martin; Constantine Frangakis; Jacobo E Mintzer; Anton P Porsteinsson; Lon S Schneider; Peter V Rabins; Cynthia A Munro; Curtis L Meinert; Constantine G Lyketsos Journal: Am J Geriatr Psychiatry Date: 2010-04 Impact factor: 4.105
Authors: George S Alexopoulos; Dimitris N Kiosses; Sibel Klimstra; Balkrishna Kalayam; Martha L Bruce Journal: Am J Geriatr Psychiatry Date: 2002 Jan-Feb Impact factor: 4.105
Authors: Jason T Olin; Lon S Schneider; Ira R Katz; Barnett S Meyers; George S Alexopoulos; John C Breitner; Martha L Bruce; Eric D Caine; Jeffrey L Cummings; Davangere P Devanand; K Ranga Rama Krishnan; Constantine G Lyketsos; Jeffrey M Lyness; Peter V Rabins; Charles F Reynolds; Barry W Rovner; David C Steffens; Pierre N Tariot; Barry D Lebowitz Journal: Am J Geriatr Psychiatry Date: 2002 Mar-Apr Impact factor: 4.105
Authors: Virginia Elderkin-Thompson; Anand Kumar; Warren B Bilker; Jennifer J Dunkin; Jim Mintz; Paul J Moberg; Raquelle I Mesholam; Ruben E Gur Journal: Arch Clin Neuropsychol Date: 2003-07 Impact factor: 2.813
Authors: Laurel D Pellegrino; Matthew E Peters; Constantine G Lyketsos; Christopher M Marano Journal: Curr Psychiatry Rep Date: 2013-09 Impact factor: 5.285
Authors: Dora Kanellopoulos; Paul Rosenberg; Lisa D Ravdin; Dalynah Maldonado; Nimra Jamil; Crystal Quinn; Dimitris N Kiosses Journal: Int Psychogeriatr Date: 2020-01-08 Impact factor: 3.878
Authors: Anton P Porsteinsson; Lea T Drye; Bruce G Pollock; D P Devanand; Constantine Frangakis; Zahinoor Ismail; Christopher Marano; Curtis L Meinert; Jacobo E Mintzer; Cynthia A Munro; Gregory Pelton; Peter V Rabins; Paul B Rosenberg; Lon S Schneider; David M Shade; Daniel Weintraub; Jerome Yesavage; Constantine G Lyketsos Journal: JAMA Date: 2014-02-19 Impact factor: 56.272
Authors: Laura B Zahodne; Katherine Ornstein; Stephanie Cosentino; D P Devanand; Yaakov Stern Journal: Am J Geriatr Psychiatry Date: 2013-07-17 Impact factor: 4.105
Authors: Sarah K Dutcher; Gail B Rattinger; Patricia Langenberg; Pankdeep T Chhabra; Xinggang Liu; Paul B Rosenberg; Jeannie-Marie Leoutsakos; Linda Simoni-Wastila; Loreen D Walker; Christine S Franey; Ilene H Zuckerman Journal: J Am Geriatr Soc Date: 2014-05-13 Impact factor: 5.562